Anuh Pharma Q1 Revenue Rises To 1.94B Rupees, Net Profit Reaches 114M Rupees

Market snapshot: Anuh Pharma Ltd has reported its standalone financial results for the first quarter ended June 30, 2026 (Q1 FY27). The company's revenue from operations rose to ₹194 crore (1.94B Rupees), showing modest top-line growth. Standalone net profit posted a notable improvement, climbing to ₹11.4 crore (114M Rupees) compared to ₹8.3 crore (83M Rupees) in the same period last year.

Data Snapshot

• Standalone revenue for Q1 FY27 reached ₹194 crore, representing a growth of ≈4.30% YoY (derived: ₹194 cr vs ₹186 cr).
• Standalone net profit for Q1 FY27 rose to ₹11.4 crore, marking an increase of ≈37.35% YoY (derived: ₹11.4 cr vs ₹8.3 cr).

What's Changed

• Sequential revenue declined by ≈4.02% from ₹202.12 crore in Q4 FY26 to ₹194 crore in Q1 FY27, though continuing on an upward trajectory year-on-year.
• Sequential standalone net profit remained highly resilient, sliding marginally by ≈2.40% from ₹11.68 crore in Q4 FY26 to ₹11.4 crore in Q1 FY27.

Key Takeaways

• Top-line stability: Standalone revenue registered a steady year-on-year growth of ≈4.30%, reaching ₹194 crore.
• Strong bottom-line expansion: Standalone net profit surged by ≈37.35% YoY to ₹11.4 crore, signaling robust margin recovery.
• Sequential resilience: Profitability held remarkably steady near Q4 FY26 levels despite a sequential decline in top-line scale.

SAHI Perspective

Anuh Pharma's Q1 FY27 performance demonstrates strong margin expansion capabilities. While the top-line growth of ≈4.30% YoY indicates stable demand, the ≈37.35% surge in net profit suggests a potential easing of input cost pressures or a more favorable product mix. This bottom-line turnaround is particularly notable given that the previous fiscal year had seen profit margin pressures due to raw material and intermediate cost escalations. The stability of profit sequentially (₹11.4 crore in Q1 FY27 vs ₹11.68 crore in Q4 FY26) despite lower revenue reflects strong operational efficiency.

Market Implications

The robust expansion in standalone profit is likely to trigger positive sentiment on the exchange, potentially driving a recovery in the stock price. The stock has witnessed a decline of ≈12.31% over the past year, trading in the ₹79-₹80 range. Sustained profitability will serve as a key catalyst, especially given the company's approved API manufacturing blocks at Tarapur, which passed a USFDA inspection with zero observations in 2026.

Trading Signals

Market Bias: Bullish

The bullish bias is supported by a robust ≈37.35% YoY expansion in standalone net profit to ₹11.4 crore, highlighting strong margin recovery despite a moderate ≈4.30% YoY revenue growth of ₹194 crore.

Overweight: API Manufacturers, Pharma & Life Sciences

Trigger Factors:

• Sustained operating margin improvement in subsequent quarters.
• Favorable management commentary in the upcoming 66th AGM scheduled on August 12, 2026.
• Commercial traction of new molecules or scaling of the Tarapur facility's expanded capacity of 2,400 MTPA.

Time Horizon: Near-term (0-3 months)

Industry Context

Anuh Pharma operates in the Active Pharmaceutical Ingredients (API) and bulk drug manufacturing segment. The API sector has faced global supply chain challenges and competitive pricing pressures over the last two years, particularly concerning intermediate imports from China. Anuh Pharma has been addressing these challenges through selective backward integration and developing in-house intermediate capabilities at its Tarapur facility, which operates at an installed capacity of 2,400 metric tons per annum.

Key Risks to Watch

• Fluctuations in the prices of key raw materials and pharmaceutical intermediates imported from China.
• Foreign exchange rate volatility, as exports contribute nearly half of the company's total sales (around 46% in FY26).
• Strict regulatory compliance requirements across diverse export markets spanning over 72 countries.

Recent Developments

Anuh Pharma's 66th Annual General Meeting (AGM) is scheduled for August 12, 2026, where shareholders will vote on a 30% final dividend (₹1.50 per share) for FY26. Additionally, the company's Tarapur manufacturing facility passed a USFDA inspection with zero observations, confirming strong adherence to global quality standards.

Closing Insight

Anuh Pharma's Q1 FY27 performance marks a robust start to the fiscal year, highlighted by strong bottom-line execution. By translating moderate revenue gains into substantial profit growth, the company highlights its operating leverage and margin resilience. Investors should monitor the upcoming AGM on August 12, 2026, for further strategic updates on capacity utilization and export expansion.

High Performance Trading with SAHI.